Previous close | 11.20 |
Open | 11.54 |
Bid | 9.65 |
Ask | 12.60 |
Strike | 30.00 |
Expiry date | 2025-08-15 |
Day's range | 11.20 - 11.54 |
Contract range | N/A |
Volume | |
Open interest | 38 |
The FDA approves Bristol Myers' (BMY) cancer drug Augtyro for the treatment of adult and pediatric patients aged 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.
PRINCETON, N.J., June 13, 2024--U.S. FDA Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive....
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.